DENVER, CO, Feb. 3 /CNW Telbec/ - Medical International Technology Inc.
(MDLH.OB) www.mitneedlefree.com is pleased to announce its progress in China.
Based on the results obtained in two separate pivotal clinical trials
over the past six months, the Chinese SFDA authorities have approved
and issued to our Joint Venture Corporation the official licence to
sell MED-JET® products.
"We are extremely delighted to have received the official certification
to sell MED-JET® products to the largest human medical market in the world," said MIT
President and CEO, Mr Karim Menassa. "We can now execute our business
plan, which forecasts multi million dollars of sales in different niche
markets as well as hospitals and clinics across all Chinese provinces.
MIT China General Manager Mr. Ethan Sun said "The official SFDA
Certification has been obtained thanks to great collaboration between
MIT China employees and hospital personnel."
Dr. Francis Bellido, Vice-President and Chief Strategy Officer of MIT
Canada believes that access to the Chinese market, with its growing
middle class population demanding more quality healthcare, could be
instrumental for MIT due to the huge volume of needle-free injectors
needed to satisfy the staggering Chinese demand"
Medical International Technology Inc. is proud to continue providing a
safe and effective means to help prevent the spread of deadly diseases
to both humans and animals through the use of the Med-Jet® and Agro-Jet® needle-free injection system.
About Medical International Technology, Inc. MIT CANADA, with offices in
Montreal, is a subsidiary of Denver, Colorado-based Medical
International Technology, Inc. (MIT USA), which specializes in the
development, production, marketing and sale of needle-free injectors
both for humans and animals, for individual and mass vaccinations.
The statements which are not historical facts contained in this press
release are forward-looking statements that involve certain risks and
uncertainties, including but not limited to risks associated with the
uncertainty of future financial results, additional financing
requirements, development and acquisition of new product lines and
services, government approval processes, the impact of competitive
products or pricing a technological changes, the effect of economic
conditions and other uncertainties, and the risk factors set forth from
time to time in the Company's SEC reports, including but not limited to
its annual report on Form 10-KSB; its quarterly reports on Forms
10-QSB; and any reports on Form 8-K. Medical International Technology
Inc. takes no obligation to update or correct forward-looking
SOURCE MEDICAL INTERNATIONAL TECHNOLOGIES INC.
For further information: